Candel Therapeutics (CADL) stock: insider trades, news & valuation
Net buyingShare price and insider trades
Candel Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $3.0M and 3 sold $3.6M of CADL stock on the open market.
Get emailed when insiders cluster-buy stocks like CADL
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CADL insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $3.2M | 3 |
| Q2 2026 | — | 0 | $306K | 2 |
| Q1 2026 | $3.0M | 1 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 1 Candel Therapeutics, Inc. insider reported open-market purchases totaling $3.0M, while 3 insiders reported sales totaling $3.6M. Among insiders with enough purchase history to measure, Paul B Manning (Director) has the highest Insider Score at 86. 5 of 5 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 11SEC | Paul Peter TakCEO | Sell Plan | 220,866172,700 held (−56%) | $11.50 | $2.5M | -13.6% | — |
| Sep 11SEC | Paul Peter TakCEO | Sell Plan | 59,379113,321 held (−34%) | $10.46 | $621K | -5.0% | — |
| Aug 19SEC | Seshu TyagarajanCTO | Sell Plan | 7,00076,865 held (−8%) | $12.00 | $84K | -17.2% | — |
| Jul 1SEC | Francesca BaroneChief Scientific Officer | Sell Plan | 23,44777,362 held (−23%) | $10.06 | $236K | -1.2% | — |
| Jul 1SEC | Seshu TyagarajanCTO | Sell Plan | 7,00083,865 held (−8%) | $10.02 | $70K | -0.8% | — |
| Feb 26SEC | Paul B ManningDirector | Buy | 550,4582,763,527 held (+25%) | $5.45 | $3.0M | +82.4% | 86 |
Insiders at Candel Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Paul B ManningDirector | $3.0M | — | Feb 26, 2026 | 86 |
| Paul Peter TakCEO | — | $3.2M | Sep 11, 2026 | — |
| Francesca BaroneChief Scientific Officer | — | $236K | Jul 1, 2026 | — |
| Seshu TyagarajanCTO | — | $154K | Aug 19, 2026 | — |
CADL stock: common questions
Are Candel Therapeutics, Inc. insiders buying CADL stock?
In the past 12 months, 1 insiders reported open-market purchases of CADL worth $3.0M. The latest was Director Paul B Manning bought $3.0M of CADL at $5.45 — first open-market purchase in our records; raises the stake by 25%.
Are Candel Therapeutics, Inc. insiders selling CADL stock?
3 insiders reported sales worth $3.6M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CADL's 52-week range?
Over the past year CADL has traded between $4.42 and $13.75. It last closed at $9.94 on Oct 9, 2026.